- NanoVibronix (NASDAQ:NAOV) has added ~18.2% in the pre-market after disclosing positive results from a study for its PainShield device in patients with lateral epicondylitis, also called tennis elbow.
- In the randomized, double-blind study conducted at Birmingham, Alabama, 91% of patients who received PainShield therapy in conjunction with over-the-counter medication had full or partial resolution of symptoms without the benefit of opioid-based prescription medication.
- An ultrasound device, PainShield, delivers a localized ultrasound effect to treat pain, inducing soft tissue healing in the area.
- At the beginning of the study, all patients had pain and point tenderness and received standard care but without pain relief.
- David Lemak, the lead investigator of the study, noted: “Most encouraging are the results we were able to achieve for our patients without the use of prescription opioid medications, which can often lead to prolonged use and addiction.”
In Q2 2021, NanoVibronix (NAOV) grew its revenue by ~18% YoY to $318K thanks to rising sales of PainShield devices to distributors.
NanoVibronix announces positive results for ultrasound device in pain study
Recommended For You
More Trending News
About NAOV Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
NAOV | - | - |
NanoVibronix, Inc. |